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ABSTRACT The contamination of drug residues, including chiral ones, is not
acceptable in earth’s ecosystem. The dynamicity of enantiomers of thalidomide and its
derivatives (3-methyl thalidomide, 3-ethyl thalidomide, and 3-butyl thalidomide) was
ascertained at supramolecular level in water-sediment system using solid phase extrac-
tion (SPE) and stereoselective HPLC. Enantiomeric separation of these drugs was car-
ried out on Ceramosphere RU-2 (25 cm 3 0.46 cm, particle size 50 lm) chiral column
using pure ethanol (1.0 ml/min) as eluent at 230 nm detection. Retention times,
capacity, separation, and resolution factors of the enantiomers of these drugs were in
the range of 20.0–36.0, 2.08–3.93, 1.35–1.57, and 1.0–2.0 min, respectively. Percentage
recoveries of the enantiomers in SPE were in the range of 90.0 to 95.0 in water-sediment
system. Langmuir and Freundlich model were best ﬁtted for dynamic equilibrium con-
centrations at different experimental parameters. Thalidomide and its derivatives follow
ﬁrst-order kinetics at dynamic equilibrium. The rate constants of chiral interconversions
were 0.390 and 0.385 days21 for S- and R-enantiomers, respectively. The uptake of thali-
domide by sediment is quite good and of endothermic nature indicating good self-puriﬁ-
cation capacity of the nature for such toxic species. Chirality 00:000–000, 2009. VC 2009
Wiley-Liss, Inc.
KEY WORDS: chiral separations; supramolecular chiral dynamics; thalidomide; water-
sediment system
INTRODUCTION
Thalidomide [a-(N-phthalimido)-glutarimide] is a seda-
tive, hypnotic, and anti-inﬂammatory medication, which
was sold from 1957 to 1961 in almost all European coun-
tries under different trade names. But it was banned in
1961 after a calamity called Thalidomide tragedy1; because
of its teratogenic nature of malformations, including pho-
comelia, in about 12,000 newly born babies of women in
46 different European countries, who had taken
thalidomide during their pregnancies.2 Later researchers
concluded that this tragedy was due to S-(2)-enantiomer
of thalidomide.3 Basically, thalidomide [a-(N-phthalimido)-
glutarimide] (Fig. 1A) consists of a two ringed structure
with an asymmetric carbon in the glutarimide ring, which
exists as an equal mixture of S-(2) and R-(1) enantio-
mers. Recently, thalidomide is used for the treatment of
various diseases such as rheumatoid arthritis, graft-versus-
host, Behcet’s syndrome, cutaneous lupus, cancer, and
refractory aphthous ulcerations in patients with AIDS in
various countries.4–9 In 1998, thalidomide has been
approved speciﬁcally for treating erythema nodosum lepro-
sum (ENL) in leprosy (Hansen’s Disease) in USA10 and
on investigational basis for the treatment of above-cited
disease in some North American countries.11–14 It has
been observed that thalidomide showed teratogenic effect
even after the administration of safe R-(1)-enantiomer
because of its rapid conversion into toxic S-(2)-form.
Some studies have been carried out in vitro on intercon-
version and stereoselectivity of thalidomide. Besides,
in vitro pharmacokinetics of thalidomide have also been
established in human beings.15–22
In natural conditions, thalidomide is degraded to more
than 20 byproducts because of rapid pH-dependent hydro-
lysis in aqueous solution. The plasma concentration of tha-
lidomide is 10–15 h depending on the age, race, and sex
of the patients. After this period, thalidomide and its
metabolites are excreted to the environment through urine
and feces. Therefore, there are good chances of contami-
nation of our natural water resources due to teratogenic
thalidomide and its derivatives, which may enter into the
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human body resulting in serious side effects. In view
of this, the study of the fate and dynamics of chiral
thalidomide and its derivatives in water and the sediment
of rivers, the most probable targets of contamination, are
important and essential. The article investigates the dy-
namics of chiral thalidomide and its derivatives in water
and sediment samples at supramolecular level and the
results are presented in this article.
EXPERIMENTAL
Chemicals and Reagents
The racemic mixtures and optically active R-(1)- and S-
(2)-forms of thalidomide and its derivatives (3-methyl thali-
domide, 3-ethyl thalidomide, and 3-butyl thalidomide) were
obtained from Ciba-Geigy (Basle, Switzerland). The solu-
tions (0.1 mg/ml) were prepared in methanol. Methanol,
ethanol, ethyl acetate, acetone, diethylether, chloroform,
hexane, and dichloromethane of HPLC grade were pur-
chased from Fisher Scientiﬁc (Fairlawn, New Jersey). Tri-
ﬂuoroacetic acid, triethylamine, sodiumdihydrogen phos-
phate, and phosphoric acids were of AR grade and were
purchased from Sigma Chemical, USA. Puriﬁed water was
prepared using a Millipore Milli-Q (Bedford, MA) water pu-
riﬁcation system. pH meter of Hach, USA, was used to mea-
sure pH of the solutions. C18 Sep-Pak Vac (1 cc) cartridge
was obtained from Waters, USA. The vacuum was gener-
ated by the homemade vacuum pump assembly. Zymark
Turbo Vap LV evaporator was obtained from Hopkinton,
USA. The chiral column Ceramosphere RU-2 (25 cm 3 0.46
cm, particle size 50 lm) was obtained from Shiseido
(Tokyo, Japan). The determination of thalidomide and its
derivatives was carried out by stereoselctive HPLC.
Chromatographic Conditions
An aliquot of 10 ll of each solution was injected on to a
HPLC system consisting of Waters solvent delivery pump
(model 510), Waters injector (model WISP 710B), Waters
tunable absorbance detector (model 484), and Waters inte-
grator (model 740). The order of elution of the enantio-
Fig. 1. Structures of (A) thalidomide and its derivatives, (B) Ceramosphere RU-2 chiral stationary phase based on a sodium magnesium silicate, and
(C) chiral separation of racemic thalidomide.
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mers was conﬁrmed by using optically active R-(1)-form
of each compounds. The column used was Ceramosphere
RU-2 (25 cm 3 0.46 cm, particle size 50 lm) [Sodium mag-
nesium silicate with optically active (1,10-phenanthroline)
ruthenium II complex, D conﬁguration, Fig. 1B]. The mo-
bile phase was ethanol, which was ﬁltered and degassed
before use. The ﬂow rates of the mobile phase were
1.0 ml/min with detection at 230 nm. The chart speed was
kept constant at 0.1 cm/min. All the experiments were car-
ried out at 238C 6 18C. The chromatographic parameters
such as capacity factor (k), separation factor (a), and reso-
lution factor (Rs) were calculated.
Solid Phase Extraction
Solid phase extraction (SPE) methodology was devel-
oped by spiking 10 ml of racemic and optically pure thalido-
mides and its derivatives (0.1 mg/l) separately to 90 ml riv-
erine waters; already ﬁltered through Whatman ﬁlter
papers No. 24. The spiked water samples were shaken for
about 5 min and pH was adjusted to 7.0 with concentrated
sodium hydroxide. The spiked water samples were kept
at room temperature overnight. C18 cartridges were precon-
ditioned using methanol (1.0 ml) followed by
water (1.0 ml). After equilibration, 100 ml of the spiked
water samples were passed through these cartridges at
0.5 ml/min ﬂow rate. Cartridges were washed with 2.0 ml
of deionized water and then dried under vacuum for
5.0 min. Racemic and optically pure thalidomides and its
derivatives were eluted from cartridges by using 5.0 ml ace-
tonitrile at 0.5 ml/min ﬂow rate. Acetonitrile extracts were
dried under air at 408C in a Zymark Turbo Vap LV evapora-
tor and redissolved in 100 nl acetonitrile separately and
respectively. Racemic and optically pure thalidomides and
its derivatives (0.1 mg/l) were also mixed with 90 ml ﬁl-
tered riverine waters; containing 1.0 g of riverine sediment
separately and respectively; shaked 5 min and kept over-
night for 24 h. The sediments were removed by centrifuga-
tion and thalidomides and its derivatives were extracted
using acetonitrile (50 ml) by sonicator. The extracted thali-
domides and its derivatives were dried under air at 408C in
a Zymark Turbo Vap LV evaporator and redissolved in
100 nl acetonitriles separately and respectively. These ace-
tonitrile solutions obtained from water and sediment sam-
ples were used to analyze chiral thalidomides and its deriva-
tives using above-cited stereoselctive HPLC conditions.
Dynamics and Kinetics
To determine the dynamics of thalidomide and its deriv-
atives, chiral adsorption studied were also carried out
using riverine water and sediment. The effect of various
parameters such as concentration of racemates, contact
time, pH, temperature, and particle size of riverine sedi-
ment was studied. The dynamics of these racemates
between sediment and water was carried out using 0.01–
0.1 mg/ml concentrations, 5–120 min contact times, 2–10,
20–408C temperatures, 1–10 g/l doses, and 0–75, 75–150,
150–210, 210–250, 250–300, 300–425 lm particle size. The
experimental protocol was adopted and used as described
elsewhere.23 The dynamics and kinetics of chiral thalido-
mide and its derivatives in natural conditions were also
evaluated by using well-known models and equations.17
The concentrations of enantiomers of thalidomide and its
derivatives in water and sediment samples were analyzed
using above-cited SPE and HPLC conditions.
RESULTS AND DISCUSSION
Chiral Separations
Chromatographic parameters such as capacity (k), sepa-
ration (a), and resolution (Rs) factors for the resolved enan-
tiomers of thalidomide and its derivatives in standard solu-
tions and riverine water and on sediment samples are given
in Tables 1 and 2, respectively. A typical chromatogram of
chiral separation of thalidomide under reported conditions
is shown in Figure 1C. A perusal of Tables 1 and 2 clearly
indicates that enantiomers of thalidomide and its derivatives
were resolved successfully. The slight lower values of chro-
matographic parameters in riverine water and sediment
may be due to interference of some other species present
in the sediment. Retention times, capacity, separation, and
resolution factors of the enantiomers of these drugs were in
the range of 20.0–36.0, 2.08–3.93, 1.35–1.57, and 1.0–2.0
min, respectively. The order of the elution was conﬁrmed
by using optically active pure R-(1)-forms of each com-
pound. It has been observed that S-(2)-enantiomer eluted
ﬁrst followed by R-(1)-enantiomer of all the studied race-
mates. A variation in the chromatographic parameters was
carried out to obtain the best resolution. To optimize the
chromatographic conditions, ethanol, acetonitrile, sodium
perchlorate, and several buffers were tested but no good re-
solution could be achieved. Ethanol containing 0.1% tri-
ﬂuoroacetic acid and triethylamine was also tested as the
mobile phases but no good resolution could be achieved.
As a result of extensive experimentation, the optimized
chromatographic conditions were developed and reported
herein.
Chiral Separation at Supramolecular Level
The supramolecular structure of the used CSP is shown
in Figure 1B and it contains a spherical clay (sodium mag-
nesium silicate) as the basic packing material with a ruthe-
nium complex [(1,10-phenanthroline) ruthenium II com-
plex, D conﬁguration] as chiral selector. It has alternative
sheets of octahedron of magnesium and tetrahedron of
silica sandwiching chiral selector resulting in chiral cav-
TABLE 1. Retention times, capacity, separation, and
resolution factors for chiral resolution of thalidomide and its










Thalidomide 26.3 36.0 2.60 3.93 1.51 1.95
3-Methyl thalidomide 25.2 35.4 2.45 3.85 1.57 2.00
3-Ethyl thalidomide 22.8 28.3 2.26 3.05 1.35 1.00
3-Butyl thalidomide 20.0 25.1 2.08 2.86 1.38 1.00
Experimental conditions: column, Ceramosphere RU-2; mobile phase,
pure methanol; ﬂow rate, 1.0 ml/min; detection, 230 nm; concentration,
0.1 mg/ml; injected amount, 5.0 ll.
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ities. Therefore, the tetrahedral and octahedral cavities
having the ruthenium complex serve as chiral baskets and
racemates can be separated once they enter these cavities.
The exact chiral recognition mechanism on this phase is
not known but it can be rationalized that the enantiomers
form transient diasteromeric complexes with ruthenium
complex, which are stabilized mainly by p-p interactions
with p electron of phenanthroline ring system. Enantio-
meric separation of these racemates is due to their pene-
tration into the tetrahedron and octahedral cavities of silica
and magnesium clay where they form transient diastereo-
meric complexes with chiral ruthenium complex which
are stabilized by p-p interactions between aromatic rings
and 1,10-phenanthroline. Besides, other interactive forces
such as steric, van der Waals forces may contribute toward
the chiral resolution on the reported CSP. Brieﬂy,
aromatic ring of each enantiomers ﬁts stereogenically in
different fashion into chiral cavities of stationary phase
which is stabilized by the p-p interactions of different mag-
nitude for both R-(1) and S-(2)-enantiomers and, hence,
the resolution of enantiomers occurred. However, stronger
hydrogen bondings are formed between hydrogen atom,
attached to N H amide group and oxygen atoms of clay.
It is important to mention that the nature of hydrogen
bonding is achiral, which binds the enantiomers strongly
to the clay and, hence, enantiomers are eluted at high
retention times. However, achiral hydrogen bondings pro-
vide sufﬁcient time to the enantiomers to rest onto ruthe-
nium complex, which may be helpful in chiral resolution.
Solid Phase Extraction
The SPE of thalidomides and its derivatives was opti-
mized by adjusting different pHs of riverine water and ﬂow
rates. The ﬂow rates of the eluting solvent (acetonitrile)
were also varied. Besides, other eluting solvents such as
ethanol, ethyl acetate, acetone, diethylether, chloroform,
hexane, dichloromethane were also tried. As a result of ex-
haustive experimentation, the optimized SPE conditions
were developed and used as mentioned in the experimen-
tal section. The percentage recoveries of thalidomide and
its derivatives were good and ranged from 95.0 to 90.0%
during dynamic equilibrium, kinetic and chiral intercon-
versions experiments. It has also been observed that per-
centage recoveries of racemic and optically active thalido-
mides were slightly higher than those of its derivatives,
which may be due to poor binding of laters with C18 mate-
rial. The poor adsorption of thalidomide derivatives on
reversed phase material of cartridges may be explained at
supramolecular level by considering steric effect of bulky
alkyl groups present in thalidomide derivatives.
Dynamics and Kinetics
To understand the fate of thalidomide and its derivatives
in nature, the dynamic equilibrium studies were carried
out in riverine water-sediment system. The study involves
adsorption on river bed sediment, dynamic equilibrium
between riverine water and sediment, kinetics and chiral
interconversions. The results of these experiments are dis-
cussed in the following sections.
Equilibrium Dynamics
The equilibrium and adsorption of thalidomide and its
derivatives were carried out at different contact time, con-
centrations, doses, pHs, particle sizes, and temperatures.
The effects of these parameters for thalidomide enantiom-
ers only are shown in Figures 2A to 3A. These ﬁgures indi-
cate that a dynamic equilibrium existed at 40 mg/l concen-
tration with 8 h contact time. The equilibrium pH was 7.0
with 8 g/l sediment dose. The effect of temperature on
dynamic equilibrium was also studied and it was observed
that the larger amount of thalidomide was on sediment at
408C indicating endothermic nature of adsorption. Among
various particle sizes studied, the maximum uptake was on
0–75 lm size but its percentage is poor in riverine bed sedi-
ment and, hence, 210–250 lm particle size was used to
carry out all studies. Basically, dynamic equilibrium was
studied for both R- and S-enantiomers of thalidomide and it
was observed that S-enantiomers adsorbed slightly higher
on sediment in comparison to R-antipode.
To ﬁnd out the mechanistic parameters associated with
thalidomide and its derivatives, the results obtained from
the above plots were analyzed by the well-known models









where, qe is the amount adsorbed (mg/g), Ce is the equi-
librium concentration of the adsorbate (mg/L), and Q0
and b are the Langmuir constants related to maximum
adsorption capacity and energy change in adsorption,
respectively (Fig. 3B). Similarly, eq. 2 was used for
Freundlich model.
TABLE 2. Retention times, capacity, separation, and resolution factors for chiral resolution of thalidomide and its
derivatives in river water and sediment
Chiral compounds tr1 S-(2) tr2 R-(1) k1 S-(2) k2 R-(1) a Rs
Thalidomide 26.2 (26.1) 35.7 (35.6) 2.58 (2.56) 3.90 (3.88) 1.51 (1.50) 1.92 (1.90)
3-Methyl thalidomide 25.1 (25.0) 35.2 (35.1) 2.42 (2.40) 3.81 (3.80) 1.57 (1.55) 2.00 (2.00)
3-Ethyl thalidomide 22.6 (22.0) 28.1 (28.0) 2.24 (2.22) 3.01 (3.00) 1.35 (1.33) 1.00 (1.00)
3-Butyl thalidomide 19.8 (19.5) 25.0 (25.0) 2.06 (2.02) 2.82 (2.80) 1.37 (1.35) 1.00 (1.00)
The values of chromatographic parameters inside and outside parenthesis correspond to water and sediment, respectively.
Experimental conditions: as in Table 1.
logqe ¼ logKF þ 1
n
logCe ð2Þ
4 ALI ET AL.
Chirality DOI 10.1002/chir
Fig. 3. Effect of (A) temperature on uptake of S-thalidomide, (B and C) Langmuir and Freundlich isotherms for S-thalidomide, and (D) plots of
log(qe/Ce) for adsorption of S-thalidomide on reverine sediment against 1/T for different concentrations.
Fig. 2. Effect of (A) contact time, (B) concentrations, (C) dose, and (D) pH on uptake of S- and R-thalidomide.
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where, qe is the amount adsorbed (mg/g), Ce is the equi-
librium concentration of the adsorbate (mg/L) and KF and
n are Freundlich constants related to the adsorption
capacity and adsorption intensity, respectively (Fig. 3C).
Langmuir and Freundlich constants are given in Tables 3
and 4, respectively. An evaluation of Figures 3B and 3C
and Tables 3 and 4 indicates the applicability and validity
of the experiments conducted.
Equilibrium Kinetics
The kinetics of thalidomide and its derivatives in nature
(riverine water-sediment system) was also studied by cal-
culating free energy, enthalpy, and entropy. The changes
in enthalpy (DH) and entropy (DS) were determined from
the slope (2DH/2.303R) and intercept (2DS/2.303R) of
the vant-Hoff’s plot [ln(qe/Ce) vs. 1/T], respectively (Fig.
3D only for S-Thalidomide). The values of DH and DS for
thalidomide derivatives were also calculated in the same
way (ﬁgures are not given). The free energy change (DG)
was calculated from the following equation:
DG ¼ DH  TDS ð3Þ
logðqe=CeÞ ¼ DH=2:303RT þ DS=2:303RÞ ð4Þ
where (qe/Ce) is called the adsorption afﬁnity and it is the
ratio of qe, the amount adsorbed per unit mass at equilib-
rium to Ce, the equilibrium concentration of the adsorbate.
The thermodynamic parameters obtained for the adsorp-
tion of thalidomide and its derivatives under investigation
are given in Table 5. Positive values of free energy indicate
that the adsorption of thalidomide and its derivative is not
spontaneous but rather slow.
The adsorption of thalidomide and its derivatives can be
considered as a reversible reaction with equilibrium estab-
lished between two phases. The Lagergren ﬁrst-order rate
eq. 6 can be applied for the determination of the adsorp-
tion rate constant.
TABLE 3. Langmuir constants of S-thalidomide and its derivatives
Compounds
Q0 (mg/g) b (l/mg)
208C 308C 408C 208C 308C 408C
Thalidomide 5.11 5.21 5.26 2.1 3 1023 1.95 3 1023 1.90 3 1023
3-Methyl thalidomide 5.00 5.11 5.15 2.0 3 1023 1.91 3 1023 1.88 3 1023
3-Ethyl thalidomide 4.91 4.96 5.00 1.92 3 1023 1.85 3 1023 1.80 3 1023
3-Butyl thalidomide 4.89 4.94 4.99 1.90 3 1023 1.82 3 1023 1.77 3 1023




208C 308C 408C 208C 308C 408C
Thalidomide 6.25 6.30 6.34 4.47 4.50 4.55
3-Methyl thalidomide 6.20 6.25 6.30 4.45 4.48 4.52
3-Ethyl thalidomide 6.16 6.20 6.26 4.40 4.45 4.50
3-Butyl thalidomide 6.12 6.15 6.20 4.36 4.40 4.46
TABLE 5. Equilibrium thermodynamic parameters







Thalidomide 1.83 3.82 5.81 56.48 0.20
3-Methyl thalidomide 1.85 3.85 5.90 50.89 0.22
3-Ethyl thalidomide 1.90 3.91 5.98 47.04 0.24
3-Butyl thalidomide 1.96 3.95 6.09 45.10 0.28
logðqe  qtÞ ¼ logqe  Kad
2:303
t ð5Þ
where qe and qt are concentrations of thalidomide and its
derivatives at equilibrium and time t, and Kad is the rate
constant. Experimental data, measured at the optimal pHs
for these molecules are plotted (ﬁgures are not given) and
plots give straight lines with a slope 2Kad/2.303, conﬁrm-
ing the applicability of the ﬁrst-order Lagergren rate
expression. Kinetic data were also analyzed by the proce-
dure given by Reichenberg18 using eqs. 7–10.

























where F is the fractional attainment of equilibrium at
time t, Qt is the amount of adsorbent taken up at time t
and Q0 is the maximum equilibrium uptake (at inﬁnite
time), Di is the effective diffusion coefﬁcient of these mol-
ecules in the adsorbent phase, B is the time constant, r0
is the radius of the adsorbent particle (sediment),
assumed to be spherical, and n is an integer that deﬁnes
the inﬁnite series solution.
The Bt values were obtained for each observed value
of F, from Reichenberg’s eq. 8. The linearity test of Bt
versus time plots was used to distinguish between the
ﬁlm diffusion and particle-diffusion-controlled adsorption.
If the plot of Bt vs. time (having slope B) is a straight line
passing through the origin the adsorption rate is gov-
erned by the particle diffusion mechanism; otherwise, it
is governed by ﬁlm diffusion. For all drugs the plots are
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linear but do not pass through the origin indicating a ﬁlm
diffusion mechanism.
Chiral Interconversions
The chiral interconversions of R- and S-thalidomide
were studied under natural conditions. The solubilities of
thalidomide and its derivatives in water are poor and,
hence, the probability of their occurrence on sediment is
high. Therefore, the chiral interconversions were studied
on sediment after their adsorption on it. Optically active
pure enantiomers of thalidomide and its derivatives were
used for chiral interconversions. The chiral interconver-
sions of S- and R-thalidomide are shown in Figures 4A and
4B and the rate constants of the chiral interconversions
were calculated by the following equation.
k ¼ ð2:303=tÞlog a=ða XÞ ð10Þ
where t is the time in days in which x amount of racemate
is formed from initial concentration (a) of pure enantio-
mers. The values of rate constants of the chiral intercon-
versions for thalidomide and its derivatives are given in
Table 6, which indicates higher rate of chiral interconver-
sions of S-enantiomers of thalidomide and its derivatives.
The values of rate constants were 0.390 and 0.385 day21
for S- and R-enantiomers respectively, indicating slightly
higher tendency of racemization of S-thalidomide. The
effects of pH and temperature were studied on the chiral
interconversions of thalidomide enantiomers. pH was var-
ied from 2.0 to 10 and the results are shown in Figure 4C,
which shows that racemization was higher at high pH (up
to 9.0) and becomes constant after this pH. The effect of
temperature was carried out at three different values, i.e.,
20, 30, and 408C and slightly higher rate of chiral intercon-
versions was observed at 408C.
Mechanism of Dynamics at Supramolecular Level
To ascertain the toxicities of thalidomide and its deriva-
tives, it is important to understand the mechanism of
dynamic equilibrium of thalidomide and its derivatives
Fig. 4. Chiral interconversion of (A) S-thalidomide and (B) R-thalidomide enantiomers in water-sediment systems and the effect of pH on the chiral
interconversions of S- and R-thalidomide.
TABLE 6. Rate constants (day21) of chiral interconversions of thalidomide and its derivatives at 308C at in water of pH 7.5
Compounds S-Thalidomide R-Thalidomide
Thalidomide 1.88/day (2.17 3 1025/second) 1.84/day (2.13 3 1025/second)
3-Methyl thalidomide 1.03/day (1.19 3 1025/second) 1.00/day (1.15 3 1025/second)
3-Ethyl thalidomide 0.99/day (1.14 3 1025/second) 0.95/day (1.10 3 1025/second)
3-Butyl thalidomide 0.94/day (1.06 3 1025/second) 0.90/day (1.04 3 1025/second)
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under natural conditions. pKa values of thalidomide and its
derivatives are more than 10.0 and, hence, these drugs
exist as neutral molecules at the experimental conditions
reported in this work. The dynamic equilibrium was found
to be ﬁlm diffusion at supramolecular level and is con-
trolled by certain forces such as van der Waal, hydrogen
bondings, steric effects. These drugs contain electronega-
tive atoms such as oxygen and nitrogen and on the other
hand sediment has hydroxyl and silicon groups. These
groups and atoms form hydrogen bondings between these
drugs and sediment. The adsorption of these drugs is
endothermic indicating a slow process at natural condi-
tions. The order of adsorption is thalidomide > 3-methyl
thalidomide > 3-ethyl thalidomide > 3-butyl thalidomide,
indicating the role of the steric effects of the alkyl groups,
i.e., methyl, ethyl, and butyl in thalidomide derivatives; in
comparison to thalidomide. In summary, various physical
forces and the structures of these drugs at supramolecular
level are responsible for different dynamic equilibrium
concentrations of the studied racemates under the
reported experimental conditions. Both thalidomide enan-
tiomers are not stable under natural conditions and, hence
get racemized. The chiral interconversions is favored at
low pH indicating a mechanism through proton exchange
phenomenon as discussed by other authors.15-18,24,25-28
VALIDATION
Validation of the developed methods was ascertained by
carrying out ﬁve sets (n 5 5) of the chromatographic and
SPE procedures under identical conditions. The regres-
sion analysis was carried out using Microsoft Excel pro-
gram and the results are given in Table 7 for chromato-
graphic and SPE procedures, respectively. Table 7 shows
that standard deviation was 60.10 and 60.05 for chromato-
graphic and SPE methods while the correlation coefﬁ-
cients (R2) and conﬁdence levels were 0.9999–0.9998% and
99.4–99.5%, respectively.
CONCLUSIONS
The presence of thalidomide and its derivatives in na-
ture is hazardous and this study indicates that most of
these drugs remain on sediment with poor concentration
in aqueous phase. Sediment has the capacity to hold these
toxic drugs and, hence, we are thankful to nature for its
self puriﬁcation power. However, there is a limit of the
sediment to hold these drugs when present at high con-
centration (more than 40 mg/l), consequently, thalido-
mide and its derivatives are supposed to be present in
water, which can enter into human body. The chiral inter-
conversions of the safe R-enantiomers to the S-toxic enan-
tiomer under natural condition is a serious phenomenon.
The present work describes the dynamics of the chiral tha-
lidomide at supramolecular level, in natural conditions.
This study may be useful to control the contamination of
earth ecosystem because of these toxic drugs. Therefore,
one should be careful before releasing waste efﬂuents,
containing thalidomide, in the nature. Such type of efﬂuent
discharges should be treated properly before their release
into the environment.
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